Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892–9.

Article  CAS  PubMed  Google Scholar 

Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–30.

Article  PubMed  Google Scholar 

Filetti S, Durante C, Hartl DM, Leboulleux S, Locati LD, Newbold K, et al. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol. 2022;33(7):674–84.

Article  CAS  PubMed  Google Scholar 

Ge M, Gao M, Cheng R, Chen X, Guan H, Lin Y, et al. CACA guidelines for holistic integrative management of thyroid cancer. Holistic Integrative Oncology. 2022;1(1):17.

Article  Google Scholar 

Health Commission Of The People’s Republic Of China N. National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version). Chin J Cancer Res. 2022;34(3):131–50.

Article  PubMed  PubMed Central  Google Scholar 

Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, et al. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6(5):e555–67.

Article  PubMed  Google Scholar 

Lin Y, Qin S, Yang H, Shi F, Yang A, Han X, et al. Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer. Clin Cancer Res. 2023;29(15):2791–9.

Article  CAS  PubMed  Google Scholar 

Chi Y, Zheng X, Zhang Y, Shi F, Cheng Y, Guo Z, et al. Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: a randomized, double-blind, multicenter phase II trial. Clin Cancer Res. 2023;29(20):4047–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin Y, Qin S, Li Z, Yang H, Fu W, Li S, et al. Apatinib vs placebo in patients with locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: the REALITY randomized clinical trial. JAMA Oncol. 2022;8(2):242–50.

Article  PubMed  Google Scholar 

Wang H, Wang J, Wang X, Zhu Y, Sun Y, Zhang X, et al. Comments on National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version). Chin J Cancer Res. 2022;34(5):447–50.

Article  PubMed  PubMed Central  Google Scholar 

Zeng H, Zheng R, Sun K, Zhou M, Wang S, Li L, et al. Cancer survival statistics in China 2019–2021: a multicenter, population-based study. J Natl Cancer Cent. 2024;4(3):203–13.

Article  PubMed  PubMed Central  Google Scholar 

Cancer Stat Facts: Thyroid Cancer: National Cancer Institute. Available from: https://seer.cancer.gov/statfacts/html/thyro.html. [cited 2024 5 October].

Taylor MH, Takahashi S, Capdevila J, Tahara M, Leboulleux S, Kiyota N, et al. Correlation of performance status and neutrophil-lymphocyte ratio with efficacy in radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. Thyroid. 2021;31(8):1226–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tahara M, Schlumberger M, Elisei R, Habra MA, Kiyota N, Paschke R, et al. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur J Cancer. 2017;75:213–21.

Article  CAS  PubMed  Google Scholar 

Tahara M, Brose MS, Wirth LJ, Suzuki T, Miyagishi H, Fujino K, et al. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer. 2019;106:61–8.

Article  CAS  PubMed  Google Scholar 

Brose MS, Worden FP, Newbold KL, Guo M, Hurria A. Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial. J Clin Oncol. 2017;35(23):2692–9.

Article  CAS  PubMed  Google Scholar 

Kiyota N, Tahara M, Robinson B, Schlumberger M, Sherman SI, Leboulleux S, et al. Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial. Cancer. 2022;128(12):2281–7.

Article  CAS  PubMed  Google Scholar 

Sugino K, Nagahama M, Kitagawa W, Ohkuwa K, Uruno T, Matsuzu K, et al. Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients. Endocr J. 2018;65(3):299–306.

Article  CAS  PubMed  Google Scholar 

Suzuki C, Kiyota N, Imamura Y, Goto H, Suto H, Chayahara N, et al. Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer. Head Neck. 2019;41(9):3023–32.

Article  PubMed  Google Scholar 

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.

Article  PubMed  Google Scholar 

Lin YS, Zhang X, Wang C, Liu YQ, Guan WM, Liang J. Long-term results of a phase II trial of apatinib for progressive radioiodine refractory differentiated thyroid cancer. J Clin Endocrinol Metab. 2021;106(8):e3027–36.

Article  PubMed  Google Scholar 

Lin YS, Yang H, Ding Y, Cheng YZ, Shi F, Tan J, et al. Donafenib in progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer: results of a randomized, multicenter phase II trial. Thyroid. 2021;31(4):607–15.

Article  CAS  PubMed  Google Scholar 

Sun D, Zhang X, Sun Y, Mu Z, Wang H, Zhang Y, et al. Early structural, biochemical, and metabolic responses to anlotinib in patients with progressive radioactive iodine refractory differentiated thyroid cancer. Endocr Pract. 2024;30(5):456–64.

Article  PubMed  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

Article  CAS  PubMed  Google Scholar 

Yang X, Li J, Li X, Liang Z, Gao W, Liang J, et al. TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer. J Nucl Med. 2017;58(2):258–65.

Article  CAS  PubMed  Google Scholar 

Mu Z, Zhang X, Sun D, Sun Y, Shi C, Ju G, et al. Characterizing genetic alterations related to radioiodine avidity in metastatic thyroid cancer. J Clin Endocrinol Metab. 2024;109(5):1231–40.

Article  PubMed  Google Scholar 

Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16(4):385–95.

Article  CAS  PubMed  Google Scholar 

Zheng X, Xu Z, Ji Q, Ge M, Shi F, Qin J, et al. A randomized, phase III study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer. Clin Cancer Res. 2021;27(20):5502–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007;246(3):466–70 discussion 70-1.

Article  PubMed  PubMed Central  Google Scholar 

Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309(14):1493–501.

Article